At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 198 enrolled
Drug / intervention
Secukinumab +1 morebiological
Likely dose
Secukinumab 1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
In Brief
A Phase 3 clinical trial evaluating Secukinumab and Placebo for Moderate to Severe Nail Psoriasis. Completed, enrolled 198 participants across 40 sites in 9 countries.
Detailed Summary
This purpose of this study was to demonstrate the efficacy of secukinumab versus placebo on nail psoriasis and to assess long-term efficacy, safety and tolerability of secukinumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Nail Psoriasis
CountriesAustralia, Belgium, Czechia, Denmark, Germany, Greece, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartJun 2013
Primary CompletionJan 2017
TodayJul 2026
First PostedMar 8, 2013
Enrollment StartJun 20, 2013
Primary CompletionJan 3, 2017
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 13.3 years ago
Interventions
Secukinumabbiological
Study treatment was provided in pre-filled 1 mL syringes.
Placebobiological
Placebo was provided in pre-filled 1 mL syringes.